ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers.
Journal
Seminars in thrombosis and hemostasis
ISSN: 1098-9064
Titre abrégé: Semin Thromb Hemost
Pays: United States
ID NLM: 0431155
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
31
8
2021
Statut:
ppublish
Résumé
Considering the profound influence exerted by the ABO blood group system on hemostasis, mainly through the von Willebrand factor and factor VIII (FVIII) complex, we have conducted a study evaluating the possible role of blood type on the risk of inhibitor development in hemophilia A. A total of 287 consecutive Caucasian patients with severe hemophilia A (202 without FVIII inhibitors and 85 with FVIII inhibitors) followed at seven Italian Hemophilia Treatment Centers belonging to the Italian Association of Hemophilia Centers (AICE) were included in the study. A higher prevalence of O blood group was detected in patients without inhibitors as compared in inhibitor patients (55 vs. 30.6%;
Identifiants
pubmed: 33525041
doi: 10.1055/s-0040-1718870
doi:
Substances chimiques
ABO Blood-Group System
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84-89Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
E.B. reports personal fees from Bayer, BioVIIIx, Novo Nordisk, Sobi, Takeda, Kedrion, and Amgen, outside the submitted work. A. C. reports personal fees from Bayer, Novo Nordisk, and Werfen, outside the submitted work. M. N. reports personal fees from Bayer, BioVIIIx, Novo Nordisk, Amgen, Octapharma, Kedrion, CSL Behring, and Takeda, outside the submitted work. C.S. reports personal fees from Takeda, Bayer, CSL Behring, Sobi, Novo Nordisk, Roche, and Pfizer, outside the submitted work. A.T. reports personal fees from Bayer, Novo Nordisk, and Roche, outside the submitted work.